Vanda Warning Letter From US FDA Leaves Firm “Puzzled”

Vanda Pharmaceuticals, Inc. expressed confusion recently after CEO Mihael Polymeropoulos received a warning letter from the US FDA regarding content on the firms website. Read more about the letter, which focused on website listings of drug indications without corresponding safety information, and the response from Polymeropoulos, who wondered why such an elevated course of action was undertaken by the FDA in this instance. “We understand the words of the letter,“ he said. “What we are puzzled by is the reasoning for this action.”